1.School of Public Health and Family Medicine,Capital Medical University,Beijing 100069,China 2. College of Life Science,Graduate University of Chinese Academy of Sciences,Beijing 100049,China 3 School of Medical Sciences, Edith Cowan University, Perth W A6027, Australia 4 Municiple Key Laboratory of Clinical Epidemiology, Beijing 100069,China
摘要:Abstract Glycosylation, links the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins.One of the important functions of glycans is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alternation of glycan chains under physiological condition and specific diseases such as cancer. Up to date, cancer and other lethal diseases could not be diagnosed at early stage because of the traditional marker’s low sensitivity and less specificity. Recent years, the development of glycan profiling technologies has offered technology support for understanding the complex glycan structures and has increased great interest in applying the technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This review summarizes the current research on finding the glycans as new cancer biomarkers.
出版日期: 2015-04-22
引用本文:
Jing-jing Wu,Jia-peng Lu,Ling Zhang,You-xin Wang,Man-shu Song,Li-juan Wu,Wei Wang. N-glycan,a biomarker in current cancer diagnosis[J]. 转化医学研究, 2012, 2(1): 70-76.
[1] Apweiler R, HermJakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta, 1999, 1473(1): 4-8.
[2] Alikhani Z, Alikhani M, Boyd CM, et al. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem, 2005, 280(13): 12087-12095.
[3] Phan UT, Waldron TT, Springer TA. Remodeling of the lectin-EGF-like domain interface in P- and L-selectin increases adhesiveness and shear resistance under hydrodynamic force. Nat Immunol, 2006, 7(8): 883-889.
[4] Gewinner C, Hart G, Zachara N, et al. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem, 2004, 279(5): 3565-3572.
[5] Choudhury A, Moniaux N, Ulrich AB, et al. MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2. Br J Cancer, 2004, 90(3): 657-664.
[6] Hakomori S. Inaugural article: the glycosynapse. Science’s STKE, 2002, 99(1): 225-232.
[7] Partridge E, Le Roy C, Di Guglielmo G., et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science, 2004, 306(5693):120-124.
[8] Knezevic A, Polas ek O, Gornik O, et al. Variability, heritability and environmental determinants of human plasma N-Glycome. J Proteome Res, 2009, 8(2): 694–701.
[9] Peracaula R, Barrabés S, Sarrats A, et al. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers, 2008, 25(4): 207–218.
[10] Izawa M, Kumamoto K, Mitsuoka C, et al. Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer. Cancer Res, 2000, 60(5): 1410–1416.
[11] Liu F, Zhang Y, Zhang X, et al. Transfection of the nm23–H1 gene into human hepatocarcinoma cell line inhibits the expression of sialyl Lewis X, a1, 3 fucosyltransferase VII, and metastatic potential. J Cancer Res Clin Oncol, 2002, 128(4):189 –196.
[12] Zhao J, Qiu W, Simeone D, et al. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res, 2007, 6(3):1126-1138.
[13] Peracaula R, Tabares G, Royle L, et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology, 2003, 13(6) :457-470.
[14] Kyselova Z, Mechref Y, Kang P, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem, 2008, 54(7): 1166-1175.
[15] Ueda K, Katagiri T, Shimada T, et al. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-Nitrobenzenesulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res, 2007, 6(9): 3475-3483.
[16] Saldova R, Royle L, Radcliffe C, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology, 2007, 17(12): 1344-1356.
[17] Vanhooren V, Laroy W, Libert C, et al. N-Glycan profiling in the study of human aging. Biogerontology, 2008, 9(5): 351–356.
[18] Varki A, Cummings R, Esko J, et al. Essentials of glycobiology. Cold Spring Harbor Laboratory Press. 1999.
[19] Durand G, Seta N. Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clin Chem, 2000, 46(6): 795-805.
[20] Wu JM. Reconsideration of tumor marker. Chin J Lab Med, 2005, 28(1): 11-13. (in Chinese)
[21] Manne U, Srivastava RG, Srivastava S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today, 2005, 10(14): 965-976.
[22] Gornik O, Wagner J, Pu i M, et al. Stability of N-glycan profiles in human plasma. Glycobiology, 2009, 19(12): 1547-1553.
[23] Kobata A. Glycobiology in the field of aging research—introduction to glycogerontology. Biochimie, 2003, 85(1-2): 13–24.
[24] Vanhooren V, Liu X, Franceschi C, et al. N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing. Mech Ageing Dev, 2009, 130(1-2): 92-97.
[25] Pucic M, Pinto S, Novokmet M, et al. Common aberrations from the normal human plasma N-glycan profile. Glycobiology, 2010, 20(8): 970-975.
[26] Rye P, Walker R. Analysis of glycoproteins released from benign and malignant human breast: changes in size and fucosylation with malignancy. Eur J Cancer Clin Oncol, 1989, 25(1): 65-72.
[27] Qiu Y, Patwa T, Xu L, et al. Plasma glycoprotein in profiling for colorectal cancer biomarker Identification by lectin glycoarray and lectin blot. J Proteome Res, 2008, 7(4): 1693-1703.
[28] Kam R, Poon T, Chan H, et al. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. Clin Chem, 2007, 53(7): 1254–1263.
[29] Liu X, Desmyter L, Gao C, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007, 46(5): 1426-1435.
[30] Norton P, Comunale M, Krakover J, et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem, 2008, 104(1):136-149.
[31] Tang Z, Varghese R, Bekesova S, et al. Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res, 2010, 9(1): 104-112.
[32] Block T, Comunale M, Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784.
[33] Liu X, Dewaele S, Vanhooren V, et al. Alteration of N-glycome in diethylnitrosamine-induced hepatocellular carcinoma mice: a non-invasive monitoring tool for liver cancer. Liver Int, 2010, 30(8): 1221-1228.
[34] An H, Miyamoto S, Lancaster K, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res, 2006, 5(7): 1626-1635.
[35] Leiserowitz G, Lebrilla C, Miyamoto S, et al. Glycomics analysis of serum a potential new biomarker for ovarian cancer. Int J Gynecol Cancer, 2008, 18(3): 470-475.
[36] Gornik O, Royle L, Harvey D, et al. Changes of serum glycans during sepsis and acute pancreatitis. Glycobiology, 2007, 17(12): 1321-1332.
[37] Royle L, Campbell M, Radcliffe C, et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem, 2008, 376(1): 1–12.
[38] Abbott K, Aoki K, Lim J, et al. Targeted Glycoproteomic identification of biomarkers for human breast carcinoma. J Proteome Res, 2008, 7(4): 1470-1480.
[39] Arnold J, Saldova R, Hamid U, et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics, 2008, 8(16): 3284–3293.
[40] Lee Y, Lin T. Determination of carbohydrates by high-performance capillary electrophoresis with indirect absorbance detection. J Chromatogr B Biomed Appl, 1996, 681(1): 87–97.
[41] Kolarich D, Altmann F. N-Glycan analysis by matrix-assisted laser desorption/ionization mass spectrometry of electrophoretically separated nonmammalian proteins: application to peanut allergen Ara h 1 and olive pollen allergen Ole e 1. Anal Biochem, 2000, 285(1): 64–75.
[42] Kim Y, Jeong H, Jang K, et al. Rapid and high-throughput analysis of N-glycans from ovarian cancer serum using a 96-well plate platform. Anal Biochem, 2009, 391(2): 151-153.
[43] Kirmiz C, Li B, An H, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics, 2007, 6(1): 43-55.
[44] Chu C, Ni onuevo M, Clowers B, et al. Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics, 2009, 9(7): 1939-1951.
[45] Lu JP, Knezevic A, Wang YX, et al. Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese Han and Croatian populations. J Proteome Res, 2011, 10(11):4959-4969.
